Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. Researchers described the case in a new study, ...
Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...
Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.
Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...
Groundbreaking gene editing treatment saves baby with rare disease — it could someday treat millions
A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. The baby, KJ Muldoon of Clifton Heights, ...
Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback